Falang Database driver not enabled

Acticor Biotech completes a 22M€ Series B

Acticor Biotech is a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke. The company recently raised 7M€ in addition to its Series B, which is now completed at 22,3M€. This additional funding is significant as it will enable the company to expand its phase II clinical trial ACTIMIS in the U.S.

The financing was led by Go Capital, alongside with CapDecisif Management, Newton Biocapital Fund and Anaxago..